BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...
Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...
Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...
Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...
Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...